Trial Profile
Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
- Indications Thrombotic thrombocytopenic purpura
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Post-HERCULES
- Sponsors Ablynx; Sanofi
- 13 Dec 2022 Results of post hoc analysis (from two studies HERCULES and post-HERCULES) assessing the efficacy and safety of caplacizumab in patients with iTTP presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 22 Sep 2022 Results assessing long-term outcomes of patients with immune-mediated thrombotic thrombocytopenic purpura with caplacizumab, published in the Journal of Thrombosis and Haemostasis.
- 17 Jun 2022 Results assessing long-term safety and efficacy of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura, and safety and efficacy of repeated caplacizumab use for acquired thrombotic thrombocytopenic purpura recurrence, presented at the 27th Congress of the European Haematology Association.